<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951206</url>
  </required_header>
  <id_info>
    <org_study_id>MHRI IRB #STUDY00003851</org_study_id>
    <nct_id>NCT04951206</nct_id>
  </id_info>
  <brief_title>Fractionated CO2 Laser With and Without Clobetasol for Treatment of Vulvar Lichen Sclerosus</brief_title>
  <acronym>VULVIE</acronym>
  <official_title>A Randomized Controlled Trial of Vulvar Fractionated CO2-Laser Therapy With and Without Concomitant Topical Clobetasol Propionate 0.05% Ointment for Treatment of Vulvar Lichen Sclerosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patty Brisben Foundation For Women's Sexual Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Society of Gynecologic Surgeons</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blind placebo-controlled trial design to determine whether&#xD;
      combining FxCO2-laser with the traditional therapy of clobetasol propionate 0.05% ointment&#xD;
      (combined treatment) as compared to FxCO2-laser and placebo ointment (FxCO2-laser only) will&#xD;
      improve treatment response in women undergoing FxCO2-laser for vulvar lichen sclerosus.&#xD;
&#xD;
      Primary objective: To evaluate if women with LS who undergo FxCO2 laser therapy and&#xD;
      concomitant TCS (clobetasol group) have higher treatment success (defined as a MCID of a ≥16&#xD;
      point improvement in Skindex-29 questionnaire) than those who undergo FxCO2 laser and placebo&#xD;
      ointment (placebo group).&#xD;
&#xD;
        -  Hypothesis: A higher proportion of women randomized to clobetasol will achieve treatment&#xD;
           success as compared to those randomized to placebo.&#xD;
&#xD;
        -  Approach: The proportion of women in each cohort who obtain a ≥16 point improvement in&#xD;
           Skindex-29 validated questionnaire score from baseline to final visit will be compared.&#xD;
&#xD;
      Secondary objectives: To compare change in pre- and post-treatment scores on validated&#xD;
      questionnaires measuring vulvovaginal symptoms, sexual function, lower urinary tract&#xD;
      function, and genital self-image between the clobetasol group compared to the placebo group.&#xD;
&#xD;
        -  Hypothesis: Women randomized to clobetasol will demonstrate an equal or greater&#xD;
           improvement on validated quality of life questionnaires measuring vulvovaginal symptoms,&#xD;
           sexual function, lower urinary tract function, and genital self-image as compared to&#xD;
           women randomized to placebo.&#xD;
&#xD;
        -  Approach: Change scores will be calculated to determine change per participant over the&#xD;
           treatment period and mean change scores will be compared between cohorts.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success</measure>
    <time_frame>About 5 months (baseline to final visit)</time_frame>
    <description>Minimally clinically important difference of a ≥16 point improvement in Skindex-29 validated questionnaire score. Skindex-29 responses are transformed to a linear scale from 0 (no effect) to 100 (effect experienced all the time), and are reported as three scale scores, corresponding to three domains (symptoms, emotions, and functioning). A reduction in Skindex-29 score of 16 points or more has been shown to indicate what is considered a clinically meaningful improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment response - vulvovaginal symptoms</measure>
    <time_frame>About 5 months (baseline to final visit)</time_frame>
    <description>Treatment response - vulvovaginal symptoms will be measured by pre- and post-treatment scores on the vulvovaginal Symptoms Questionnaire, a 21-item survey measuring vulvovaginal symptoms in postmenopausal women.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response - sexual function</measure>
    <time_frame>About 5 months (baseline to final visit)</time_frame>
    <description>Treatment response - sexual function will be measured by pre- and post-treatment scores on the Female Sexual Function Index, a validated questionnaire to assess sexual function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response - genital self image</measure>
    <time_frame>About 5 months (baseline to final visit)</time_frame>
    <description>Treatment response - genital self image will be measured by pre- and post-treatment scores on the Female Genital Self Image Scale, a validated survey with scores ranging from 7-28 with higher scores indicate a more positive genital self-image.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment response - lower urinary tract function</measure>
    <time_frame>About 5 months (baseline to final visit)</time_frame>
    <description>Treatment response - lower urinary tract function will be measured by pre- and post-treatment scores on the LURN SI-10, a 10-item questionnaire with scores ranging from 0 to 38 (higher scores = worse symptoms/bother).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant-perceived improvement</measure>
    <time_frame>Final study visit at 4-6 weeks after third Fractionated CO2 laser treatment - one time question</time_frame>
    <description>Patient Global Impression of Improvement (PGI-I): a one single item question that will ask participants to rate their improvement after undergoing treatment on a 7-point Likert scale ranging from &quot;very much worse&quot; to &quot;very much better.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant-perceived treatment satisfaction</measure>
    <time_frame>Final study visit at 4-6 weeks after third Fractionated CO2 laser treatment - one time question</time_frame>
    <description>Level of satisfaction with treatment: a one single item question that will ask participants to rate their level of satisfaction with treatment on a 5-point Likert scale from &quot;very dissatisfied&quot; to &quot;very satisfied&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">184</enrollment>
  <condition>Vulvar Lichen Sclerosus</condition>
  <arm_group>
    <arm_group_label>Clobetasol Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clobetasol propionate 0.05% ointment is the active ingredient that will be compounded and combined with base ointment. Participants will be instructed to apply 1-3 clicks of the ointment dispensed via topiclick (35 gram) dispenser to the affected tissues once daily for 1 month, then 2-3 times a week for the remainder of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo ointment will be identical in base ingredients but it will not contain clobetasol propionate. Participants will be instructed to apply the ointment to the affected tissues once daily for 1 month, then 2-3 times a week for the remainder of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractionated CO2-laser</intervention_name>
    <description>All women will be undergoing FxCO2-laser therapy as this treatment is a criterion for enrollment.</description>
    <arm_group_label>Clobetasol Group</arm_group_label>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol Propionate 0.05% Ointment</intervention_name>
    <description>Clobetasol propionate 0.05% will be compounded and prepared by a licensed pharmacist using clobetasol propionate powder (micronized, USP; manufactured by Letco Medical, LLC; NDC# 62991-1492-01) combined with base ointment (over-the-counter good neighbor pharmacy petroleum jelly, NDC# 24385-0092-27).</description>
    <arm_group_label>Clobetasol Group</arm_group_label>
    <other_name>Clobetasol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women with biopsy confirmed or clinically suspected LS&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
          -  Electing to undergo Fractionated CO2-laser therapy&#xD;
&#xD;
          -  Willing and able to undergo concomitant 0.05% clobetasol propionate treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior surgery with placement vaginal mesh for repair of pelvic organ prolapse (does&#xD;
             not include vaginal mesh for anti-incontinence procedure &quot;sling&quot; or prior mesh&#xD;
             sacrocolpopexy)&#xD;
&#xD;
          -  Prior laser, topical immunomodulators or systemic therapy for LS&#xD;
&#xD;
          -  Active genital infection^&#xD;
&#xD;
          -  Suspicious vulvar lesion that has not been evaluated&#xD;
&#xD;
          -  Known vulvar or vaginal malignancy or active treatment for other malignancy&#xD;
&#xD;
          -  Planning pregnancy&#xD;
&#xD;
          -  Prior pelvic radiation therapy&#xD;
&#xD;
          -  Topical corticosteroid use on the vulvovaginal tissues in the past 2 weeks*&#xD;
&#xD;
          -  Contraindication or allergy to clobetasol propionate 0.05%&#xD;
&#xD;
               -  Eligible for inclusion after washout period of 2 weeks ^Eligible for inclusion&#xD;
                  after treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This study is investigating treatment of vulvar lichen sclerosus and thus participants will be limited to women with vulvar lichen sclerosus</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexis Dieter, MD</last_name>
    <phone>202-877-6526</phone>
    <email>Alexis.a.dieter@medstar.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaiser Permanente - Southern California Permanente Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92110</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kimberly Ferrante</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MedStar Health</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alexis Dieter, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cheryl Iglesia</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Margaret Mueller</last_name>
    </contact>
    <investigator>
      <last_name>Kimberly Kenton</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Walter Reed National Military Medical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Christine Vaccarro</last_name>
    </contact>
    <investigator>
      <last_name>Meagan Simpson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Emily Von Bargen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Kate Meriwether</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Ladin Yurteri-Kaplan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lisa Hickman</last_name>
    </contact>
    <investigator>
      <last_name>Silpa Nekkanti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Institute for Female Pelvic Medicine &amp; Reconstructive Surgery</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Akira Gillingham</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waukesha Memorial Hospital</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sarit Aschkenazi-Steinberg</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chren MM. The Skindex instruments to measure the effects of skin disease on quality of life. Dermatol Clin. 2012 Apr;30(2):231-6, xiii. doi: 10.1016/j.det.2011.11.003. Epub 2011 Dec 20. Review.</citation>
    <PMID>22284137</PMID>
  </reference>
  <reference>
    <citation>Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, Ferguson D, D'Agostino R Jr. The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000 Apr-Jun;26(2):191-208.</citation>
    <PMID>10782451</PMID>
  </reference>
  <reference>
    <citation>Herbenick D, Schick V, Reece M, Sanders S, Dodge B, Fortenberry JD. The Female Genital Self-Image Scale (FGSIS): results from a nationally representative probability sample of women in the United States. J Sex Med. 2011 Jan;8(1):158-66. doi: 10.1111/j.1743-6109.2010.02071.x. Epub 2010 Nov 2.</citation>
    <PMID>21044269</PMID>
  </reference>
  <reference>
    <citation>Herbenick D, Reece M. Development and validation of the female genital self-image scale. J Sex Med. 2010 May;7(5):1822-30. doi: 10.1111/j.1743-6109.2010.01728.x. Epub 2010 Mar 3.</citation>
    <PMID>20233278</PMID>
  </reference>
  <reference>
    <citation>Hodges KR, Wiener CE, Vyas AS, Turrentine MA. The Female Genital Self-image Scale in Adult Women With Vulvar Lichen Sclerosus. J Low Genit Tract Dis. 2019 Jul;23(3):210-213. doi: 10.1097/LGT.0000000000000481.</citation>
    <PMID>31135654</PMID>
  </reference>
  <reference>
    <citation>Cella D, Smith AR, Griffith JW, Kirkali Z, Flynn KE, Bradley CS, Jelovsek JE, Gillespie BW, Helfand BT, Talaty P, Weinfurt KP; LURN Study Group. A New Brief Clinical Assessment of Lower Urinary Tract Symptoms for Women and Men: LURN SI-10. J Urol. 2020 Jan;203(1):164-170. doi: 10.1097/JU.0000000000000465. Epub 2019 Jul 31.</citation>
    <PMID>31364922</PMID>
  </reference>
  <reference>
    <citation>Erekson EA, Yip SO, Wedderburn TS, Martin DK, Li FY, Choi JN, Kenton KS, Fried TR. The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause. 2013 Sep;20(9):973-9. doi: 10.1097/GME.0b013e318282600b.</citation>
    <PMID>23481118</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clobetasol propionate</keyword>
  <keyword>Fractionated CO2-laser</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vulvar Lichen Sclerosus</mesh_term>
    <mesh_term>Lichen Sclerosus et Atrophicus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

